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Summary Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody
OC125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological
types of carcinoma were antigen positive and there was a positive correlation between the frequency and level
of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125
estimations following a prospective protocol. Variation in CA125 level reflected disease progression or
regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week
following chemotherapy and this effect predicted a good response to treatment. The natural half-life of
CA125 in serum was estimated at -4.8 days, sufficiently short to allow changes in tumour volume to be
rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin
lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian
adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125
in the management of ovarian malignancy is discussed.
The natural history of malignant ovarian tumours,
which includes local invasion of tissues deep within
the pelvis and the frequent presence of peritoneal
seedling metastases prevents early diagnosis of the
disease and once the diagnosis has been made,
hinders accurate monitoring of disease status. Of
currently available methods, CAT scanning
increases the information available, even after
recent laparotomy (Johnson et al., 1983) and
despite limitations in detecting peritoneal seedlings
and the logistical difficulties of repetition at
monthly intervals, it remains the most useful non-
invasive technique in common use. Second-look
laparotomy which can accurately detect residual or
recurrent disease, has been advocated to determine
an end point for chemotherapy (Smith et al., 1976;
Cohen et al., 1983). However this has not resulted
in improved survival (Cohen et al., 1983) and its
place in overall management remains unclear. The
introduction of intensive combination chemo-
therapy has improved response rates and median
survival and has emphasised the need for an
effective marker in this disease.
Several antigens have been detected in association
with ovarian carcinomas (Donaldson et al., 1980;
Bast et al., 1981; Bhattacharya et al., 1982) and of
these CA125 has shown the most clinical promise
to date (Bast et al., 1983; Canney et al., 1984).
CA125, a high molecular weight glycoprotein
expressed in coelomic epithelium during embryonic
development, is defined by a murine monoclonal
antibody raised against a serous ovarian carcinoma
cell line, OVCA 433. A radioimmunoassay to detect
CA125 in serum has been developed by Bast et al.
(1983) and the object of this study was to assess its
potential as a marker for established ovarian
cancer.
Patients and methods
The sera of 58 patients with histologically proven
ovarian carcinomas, of all histological types, were
examined for CA125 levels. All patients had known
persistent or recurrent disease. Patients with newly
diagnosed disease who were considered by the
referring gynaecologist to have residual tumour
after laparotomy and were suitable for
chemotherapy, were entered into a prospective trial
to assess the value of CA125 as a tumour marker.
Chemotherapy consisted of a combination of cis-
platinum and doxorubicin administered at 4 weekly
intervals to a total of 6 courses. CA125 levels were
measured prior to each course of chemotherapy.
Serial CA125 levels were measured in several
patients during the first week following the initial
course ofchemotherapy.
Measurement of disease response, stability or
progression was based upon clinical examination
and CAT scanning. A response required a
regression of measurable disease by >50%, whilst
disease progression required an increase in
measurable disease of >25%.
Seven patients have had serial CA125 levels
measured following apparent complete resections of
©) The Macmillan Press Ltd., 1984
Correspondence: P.A. Canney
Received 17 July 1984; accepted 16 September 1984.766 P.A. CANNEY et al.
early stage ovarian carcinomas. A further 41
patients with non-ovarian neoplasms were also
tested to determine the specificity of the antigen.
CA125 was measured using a commercially
available kit (Centacor inc. Malvern. Penn USA)
Briefly, this is a simultaneous sandwich solid phase
radioimmunoassay. Polystyrene beads coated with
OC125 antibody as an immunoabsorbant to bind
CA125 present were incubated overnight with
100 dl aliquots of 1251 labelled OC125 in trace
buffer, specimen sera, standards and internal
control. Serum and excess 1251 labelled OC125 was
washed from the specimen and the activity
associated with the immunoabsorbant counted on a
gamma counter. Internal standards, comprising
graded dilutions of partially purified CA125 antigen
(quantified in arbitrary units) were used to
construct a standard curve of concentration versus
bound radioactivity from which the concentration
of CA125 in sera and internal control could be
determined. The internal control provided was
119.1uml-1. The experimental value observed
during the 24 assay runs in this series was
117.5+6.4uml-1.
Serum samples were separated within 4h of
collection and stored at -20°C until required.
Half-lives have been calculated to the point where
the antigen level entered the normal range. The
upper limit of normal was taken as 35Uml-1, a
level exceeded by 1% of 888 blood donors, (Bast et
al., 1983).
Results
Sensitivity
The proportion of patients with ovarian carcinomas
having elevated CA125 levels is shown in Table I,
the overall sensitivity being 83%. The antigen was
detectable irrespective of histological type, but
whether the frequency of detection in mucinous,
endometroid and clear cell carcinoma was similar
Table I Serum CA125 antigen in ovarian
carcinoma: Frequency of detection overall and
by histological type
Histology No. Positivea %
Serous 27 22 81
Mucinous 6 6 100
Endometroid 6 4 60
Clear cell 4 2 50
Undifferentiated 15 14 93
Total 58 48 83
aPositive assay
level >35uml-'.
defined as serum CA125
to the larger sub-groups, comprising 72% of
patients, could not be ascertained from this series.
CA125 levels were positively correlated with
tumour burden (Table II), the frequency of positive
sera rising from 63% of patients with <2cm
diameter tumours to 100% of patients in whom
bulk of residual disease exceeded 10cm in diameter.
This increased frequency corresponded to a mean
fold increase of 4.4 and a maximum fold increase of
250 in serum antigen level.
Table II Serum CA125 antigen in ovarian carcinoma:
Levels by bulk of residual disease at presentation
Mean (range)
Bulk ofdisease No. Positive (%) (Positivepatients)
<2cm 16 10 (63) 234 (39-470)
2-10cm 17 13 (76) 254 (39-1500)
>10cm 24 24(100) 1021 (87-9720)
Specificity
The frequency of CA125 antigen detection in the
sera of patients with non-ovarian tumours is shown
in Table III. The antigen was not detected in non-
Hodgkin lymphoma. However 11/27 adeno-
carcinomas of different provenance, some of which
are included in the major differential diagnoses of
ovarian carcinoma, were positive. The specificity
for this heterogeneous sub-group as a whole was
58%.
Table III Comparison of serum CA125
antigen levels in ovarian and non-
ovarian tumours
Tumour type No. Positive %
All ovarian 58 48 83
carcinoma
N.H.L. 15 0 0
Colon 10 2 20
Uterus 8 4 50
Adenocarcinoma
Cervix 3 2 66
Othera 6 2 33
aAdenocarcinoma of kidney 1, parotid
1, ljing 1, breast 2, pancreas 1.
Correlation with tumour response
Twenty patients were assessable for response to
chemotherapy and correlation with clinical response
is shown in Table IV. For the patients who had
falling antigen levels, despite apparent static disease
the mean half-life of the antigen was 22.6+2.2CA125 ANTIGEN AS A TUMOUR MARKER 767
Table IV Variation in CA125 levels with
disease status in response to chemotherapy
Clinical status
CA125 Response Static Progress
Fall 12a 3b 0
Static 0 1 1
Rise 0 0 6
(patients who initially responded but later
relapsed have both events included).
'Half life 9.2+4.9 days.
bHalf life 22.6+2.2 days.
days. By contrast the mean half-life of the antigen
in those patients who obtained a good response
to chemotherapy was much shorter at 9.2+4.9
days. The antigen fell exponentially in response to
chemotherapy and tended to plateau well within the
normal range, dividing the serial measurements into
two distinct phases (Figure la). The mean plateau
level was 11.3+4.3 Uml- 1.
In 9 patients serial measurements were performed
following the first course of chemotherapy. Three
patients showed an acute rise of >50% of the
pretreatment level (I130-2480 Uml -1; 1520-
5000 Uml-1 and 110-21OUml-1) and all of these
proceeded to obtain a good response to
chemotherapy (Figure lb). Of the 3 patients not
demonstrating such an acute rise who were
available for assessment, response to chemotherapy
was poor.
Three patients in whom disease progressed
following an initial transient response to
chemotherapy demonstrated a rising antigen level
several weeks prior to clinical evidence of
progression (Figure lc).
One patient, who had complete removal of all
macroscopic tumour, had serial levels performed
after operation: the half-life of the antigen was 4.8
days. All 7 patients who had serial serum antigen
levels performed following complete resection of
early stage tumours, had antigen levels within the
normal range, 12.1 +5.3 Uml 1, at between 22 and 90
days post-operatively and no patient has relapsed
to date. (median follow-up 8 months).
Discussion
No additional information would be obtained from
the radioimmunometric assay if the data coincided
exactly with those from clinical and radiological
methods: only long term follow-up will determine
the place of the immunoassay in clinical practice.
However, several points have been established by
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Figure 1 (a) The exponential decline in CA125
antigen level and plateau well within the normal range, typical of 12 patients obtaining a good response to
chemotherapy. (b) The acute rise in CA125 antigen level in the week following the initial course of
chemotherapy, typical of 3 patients. (c) CA125 antigen levels in a patient initially responding to
chemotherapy, and subsequently during progression of
disease. The rise in antigen level preceded clinical
relapse by 4 weeks.
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this study. The sensitivity is more than adequate,
and extends to all histological types of epithelial
neoplasms, including mucinous tumours which were
originally reported as negative (Bast et al., 1983;
Kabawat et al., 1983). However, all reports have
included only small numbers of patients with
mucinous tumours and, although pathological
opinion may vary slightly between centres, a purely
statistical effect could account for the apparent
discrepancy. The association of the antigen with
other epithelial neoplasms is such that the
specificity of the assay is poor, particularly in
regard to other adenocarcinomas which form the
major differential diagnosis of ovarian cancer.
Whilst this imposes obvious limitations on its use
as a diagnostic aid to differentiate between
adenocarcinomas of different origin and effectively
prevents screening for occult disease by means of
the immunoassay being a viable proposition, it does
not affect its potential value as a marker for
histologically proven ovarian malignancy.
The wide range of positive values observed,
particularly in the sera of patients with bulk
tumours, indicates that the proportion of antigen-
releasing cells varies from tumour to tumour, and
in some cases a considerable overall tumour volume
is required for serological detection. This is
consistent with the known antigenic heterogeneity
of ovarian neoplasms (Kabawat et al., 1983). Our
data suggest that most, if not all, ovarian tumours
express the antigen, but in only 63-76% of cases is
sufficient antigen released for detection of small
tumour volumes. In those tumours which express
and release high quantities of antigen per unit
volume, even small changes in overall tumour size
are accurately reflected by a corresponding change
in serum antigen level. In this group the marker
will be most accurate for the monitoring of therapy
or detecting relapses.
The natural serum half-life of a marker must be
short enough for the test to monitor changes in
tumour volume within a reasonable time period. A
realistic aim for chemo- or radiotherapy is the 9.2
day half-life observed in those patients who
eventually obtained good responses. However,
following surgical excision, where tumour debulking
is immediate, the decline in antigen level should
correspond to the natural serum half-life, estimated
at 4.8 days, if that excision is complete.
A progressive rise in antigen level was observed
in the sera of all patients who did not respond to
treatment. By contrast no such increases were
exhibited by responding patients, a finding which in
conjunction with the estimated half-life allows
identification of non-responders as early as one
month after the first course of treatment. A
declining antigen level was less reliable, although
when viewed in conjunction with the half-life of the
decline, it was possible to differentiate between
patients who responded and those in whom disease
only stabilised. Furthermore, the patients who
exhibited a slowly falling antigen level despite
apparently static disease all had gross bulk tumour
and a relatively low initial antigen level; a situation
where the assay is unlikely to be particularly
sensitive.
A progressive increase in serum antigen level
prior to clinically evident relapse is vital if the
marker is to be of value as part of a follow-up
programme after apparent complete resection of
early stage ovarian tumours, and for monitoring
the progress of patients who have completed
chemotherapy. This has been shown to occur in the
latter instance and is also likely to do so in the
former. However, pre- and post-operative antigen
levels would be necessary to determine the reliance
which could be placed on the test in this context.
The acute rise in serum antigen level following
chemotherapy is probably due to tumour lysis in-
situ. This appears to give very early evidence that a
given tumour has been affected by treatment and
may allow some indication of the sensitivity of the
tumour to chemotherapy.
Although an "upper limit of normal" of
35 Uml-1 must be accepted, a value below this
cannot be equated with complete clinical response
(Bast et al., 1983). The plateau level of 11.3Uml-1,
which corresponds closely to the levels seen
following complete resection of early stage tumours,
is likely to be a more realistic goal, but, by analogy
with testicular tumour markers, the end-point for
therapy is likely to be a number of courses beyond
such marker remission (Newlands et al., 1980),
which number has yet to be determined. Extended
follow-up should establish this.
In conclusion, the potential benefits of a tumour
marker in monitoring therapy may be defined as a
reduction of toxicity by avoidance of ineffective or
excessive treatment and improvement in overall
survival byallowing effective treatment to be adjusted
to the needs of the individual. Furthermore the
potential for rapid assessment of chemotherapeutic
regimens using a marker allows improvements to
occur at an accelerated rate to the benefit of all,
even marker negative patients. The sensitivity of
CA125 for established ovarian carcinoma and the
close relationship to clinical and radiological
changes in response to treatment are likely to have
a profound effect upon management of this disease.
The poor specificity limits the diagnostic utility in
patients with proven adenocarcinoma and precludes
CA125 estimation being used as a screening method
for asymptomatic patients. However, the diagnostic
and prognostic significance of elevated CA125CA125 ANTIGEN AS A TUMOUR MARKER 769
levels pre-operatively have yet to be determined.
Further investigation is needed in the above areas
as well as to evaluate its potential use in the
management of other non-ovarian
adenocarcinomas.
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